Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Ask around about tissue repair or injury recovery, and the same two names keep surfacing: BPC-157 and TB-500. Both are research peptides. Longstanding research-grade suppliers such as Kylo Peptides sell them online for research use only. Scope is the core difference. BPC-157 research focuses on localized tissue repair, while TB-500 research focuses on broader cellular […]

The post BPC-157 vs TB-500: What’s the Difference? appeared first on Medical News Bulletin.

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Professional home care has become an increasingly significant part of our aging safety net for seniors. Whether your family needs temporary help following a hospital stay, ongoing companion and mobility support, or nursing care, there is a thoughtful way to tailor services and deliver support in a way that feels just right for your loved […]

The post What To Expect From Professional Home Care In Ottawa  appeared first on Medical News Bulletin.

The United States Special Senate Committee on Aging recently held the first-ever congressional hearing on menopause, discussing barriers to care and potential solutions.
Lynne Coslett-Charlton, MD, FACOG, MSCP, a board-certified gynecologist, told Healio she was proud to testify during the hearing “on behalf of my patients and women across the country to advocate for increased federal investment in research and expanded access to menopause care.”
“Too many women suffer needlessly with burdensome symptoms of menopause due to substantial barriers to care such as physician shortages in rural areas

The FDA approved combination imlunestrant plus abemaciclib for adults with hormone therapy-resistant estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
The combination therapy (Inluriyo and Verzenio, Eli Lilly & Co.) was approved with the indication for certain patients with endocrine therapy-resistant advanced breast cancer as detected by a companion diagnostic assay (Guardant360 CDx, Eli Lilly & Co.), which also received approval, according to an FDA press release.
Approval of the combination therapy was based on the results of the phase 3

PHOENIX — The Myopia Collective added 22 new “change agents,” as well as its first group of 19 student change agents, to foster greater support for and awareness of childhood myopia treatment, according to a press release.
The initiative, which was founded as a partnership between the American Optometric Association and CooperVision, has empowered designated change agents across the U.S. to lead advocacy efforts for childhood myopia.
“It’s really giving that voice to the profession to say, ‘This is what we can do; this is how we’re able to drive this forward [and] make this a standard of care

Data from a phase 3 study assessing more than 5,000 women and 500 pregnancies support the use of long-acting lenacapavir as HIV pre-exposure prophylaxis among pregnant, postpartum and lactating women, researchers said.
Lenacapavir (Yeztugo, Gilead) is administered via two injections given every 6 months. It has been approved for treatment in the United States for people with drug-resistant HIV since 2022, and for HIV PrEP since 2025.
PURPOSE 1 was landmark phase 3 trial conducted among cisgender women in two South African countries in which none of the participants who received lenacapavir

Results presented at the American Orthopaedic Foot & Ankle Society Annual Meeting showed patients who underwent a minimally invasive Lapidus procedure for hallux valgus had similar outcomes as those who underwent an open Lapidus procedure.
“Surgeons who do the [Lapidus] procedure either open or minimally invasive can feel confident and continue doing the same procedures that they do to have good outcomes,” Scott J. Ellis, MD, foot and ankle surgeon at Hospital for Special Surgery, told Healio.
Ellis, along with A. Holly Johnson, MD, and colleagues, retrospectively reviewed

The FDA has approved Fayuvi to treat children with mucopolysaccharidosis type IIIA, or Sanfilippo syndrome type A.
“Gene therapy holds tremendous promise for rare diseases like Sanfilippo syndrome type A,” acting FDA Commissioner Kyle Diamantas, JD, said in a press release.
Children with MPS IIIA do not produce enough sulfamidase, or they are missing it entirely. This leads to the accumulation of heparan sulfate in the body and brain, causing patients to lose cognitive, language and other developmental abilities.
There are four types of Sanfilippo syndrome, depending on the deficient

Meibomian gland dysfunction is a disruption of the meibomian glands, which are vital for producing the lipid layer of the tear film.
Meibomian gland dysfunction (MGD) affects about 38% to 68% of individuals older than the age of 40 years (Stapleton et al.), although the prevalence of MGD is difficult to accurately estimate because MGD is frequently asymptomatic (Viso et al.). MGD is both common and yet underdiagnosed.
In traditional MGD, meibomian gland oils become viscous/thickened instead of having a healthy olive oil-like consistency. This results in clogging, causing back pressure and

In the past, the CDC’s Advisory Committee on Immunization Practices routinely issued recommendations on seasonal influenza shots prior to the start of the fall and winter flu season.
Not this year.
With the ACIP in a state of limbo since a federal judge’s ruling in March blocked HHS Secretary Robert F. Kennedy Jr.’s selections for the panel, leading medical groups stepped up to issue science-based vaccine recommendations for the fall respiratory disease season.
The recommendations include guidance for adults aged 65 years or older, who are eligible to receive one of three